J. Goldman & Co’s Gyre Therapeutics GYRE Stock Holding History

J. Goldman & Co’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-16,000	Closed	-$1.4M	–	315
2018 Q2	$1.4M	Buy	+16,000	New	+$2.81M	0.07%	234

Other funds holding GYRE

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

J. Goldman & Co's GYRE Position: Q4 2021 in Review

J. Goldman & Co sold out of Gyre Therapeutics (GYRE) in Q4 2021, closing a stake of 8,101 shares — an estimated $250K sold.

J. Goldman & Co first reported a position in GYRE in Q3 2013 and held it in 6 quarters. The position peaked at $4.68M in Q1 2018. 51 funds tracked by Wall St. Rank hold GYRE as of Q4 2021.

J. Goldman & Co reported no remaining Gyre Therapeutics position as of Q4 2021 after selling out during the quarter.
J. Goldman & Co sold 8,101 Gyre Therapeutics shares in Q4 2021, an estimated $250K.
J. Goldman & Co first reported a position in Gyre Therapeutics in Q3 2013 and held it in 6 quarters.
J. Goldman & Co's Gyre Therapeutics position peaked at $4.68M in Q1 2018.
51 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2021.

Based on J. Goldman & Co's 13F filing for Q4 2021, filed 14 Feb 2022.